6-甲氧基-1-萘酚 | 22604-07-5

• 物质功能分类: 化学试剂 - 有机试剂 - 酚类
• 分子结构分类: 有机化合物 - 苯类化合物 - 萘
• 中文名称: 6-甲氧基-1-萘酚
• 英文名称: 6-methoxy-1-naphthol
• 英文别名: 6-methoxynaphthalen-1-ol；1-hydroxy-6-methoxynaphthalene
• CAS: 22604-07-5
• 化学式: C₁₁H₁₀O₂
• mdl: MFCD03695468
• 分子量: 174.199
• InChiKey: LPPSENSUXVOOII-UHFFFAOYSA-N

物化性质

• 熔点：
  85 °C(Solv: ligroine (8032-32-4))
• 沸点：
  336.7±15.0 °C(Predicted)
• 密度：
  1.193±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.6
• 重原子数：
  13
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.09
• 拓扑面积：
  29.5
• 氢给体数：
  1
• 氢受体数：
  2

安全信息

• 海关编码：
  2909500000
• 危险性防范说明：
  P261,P305+P351+P338
• 危险性描述：
  H302,H315,H319,H335
• 储存条件：
  2-8°C

反应信息

• 作为反应物：
  描述：

  6-甲氧基-1-萘酚 在 水 、 sodium 、 caesium carbonate 作用下， 以 乙醇 、 N,N-二甲基甲酰胺 为溶剂， 生成 8-propan-2-yloxyspiro[2,4-dihydro-1H-naphthalene-3,5'-imidazolidine]-2',4'-dione
  参考文献：
  名称：

  Structure–Activity relationship of linear peptide Bu-His-DPhe-Arg-Trp-Gly-NH2 at the human melanocortin-1 and -4 receptors: histidine substitution

  摘要：

  Systematic substitution of His(6) residue using non-selective hMC4R pentapeptide agonist (Bu-His(6)-DPhe(7)-Arg(8)-Trp(9)-Gly(10)- NH2) as the template led to the identification of Bu-Atc(6)(2-aminotetraline-2-carboxylic acid)-DPhe(7)-Arg(8)-Trp(9)-Gly(10)-NH2 which showed moderate selectivity towards hMC4R over hMC1R. Further SAR studies resulted in the discovery of Penta-5-BrAtc(6)-DPhe(7)-Arg(8)-Trp(9)-Gly(10)-NH2 and Penta-5-Me(2)NMAtc(6)-DPhe(7)-Arg(8)-Trp(9)-Gly(10)-NH2 which are potent hMC4R agonists and are inactive in hMC1R, hMC3R and hMC5R agonist assays. (C) 2002 Published by Elsevier Science Ltd.

  DOI：

  10.1016/s0960-894x(02)00830-2
• 作为产物：
  描述：

  6-甲氧基萘-1-胺 在 硫酸 、 溶剂黄146 、 sodium nitrite 作用下， 生成 6-甲氧基-1-萘酚
  参考文献：
  名称：

  Byrde et al., Biochemical Journal, 1959, vol. 72, p. 344,345

  摘要：

  DOI：

文献信息

• Palladium-Acid Co-Catalyzed Cleavage of Alkynoates to Construct Dibenzo[c,h]xanthene Derivatives
  作者：Bo-Cheng Tang、Miao Wang、Jin-Tian Ma、Zi-Xuan Wang、Yan-Dong Wu、An-Xin Wu

  DOI：10.1002/adsc.201800770

  日期：2018.10.18

  A novel palladium‐acid co‐catalyzed C(sp)−C(sp2) cleavage of alkynoates for the construction of dibenzo[c,h]xanthene derivatives is reported. A catalytic amount of triflic acid (TfOH) afforded an efficient transformation into the final product. Furthermore, a reduction process of alkynoates was observed during the formation of dibenzo[c,h]xanthene, preliminary mechanistic studies indicated that the

  报道了一种新颖的钯酸共催化炔烃的C（sp）-C（sp 2）裂解，用于构建二苯并[c，h]氧杂蒽衍生物。催化量的三氟甲磺酸（TfOH）有效转化为最终产物。此外，在二苯并[c，h] x吨的形成过程中观察到了炔酸的还原过程，初步的机理研究表明，二苯并[c，h] x吨的新形成的甲基质子化主要来自水。
• Novel lapachone compounds and methods of use thereof
  申请人：Ashwell Mark A.

  公开号：US20090105166A1

  公开（公告）日：2009-04-23

  The present invention provides novel tricyclic spiro-oxathiine naphthoquinone derivatives, a synthetic method for making the derivatives, and the use of the derivatives to induce cell death and/or to inhibit proliferation of cancer or precancerous cells. The naphthoquinone derivatives of the present invention are related to the compound known as β-lapachone (3,4-dihydro-2,2-dimethyl-2H-naphtho(1,2-b)pyran-5,6-dione).

  本发明提供了一种新型的三环螺-氧杂硫杂萘醌衍生物，一种制造该衍生物的方法，以及利用该衍生物诱导细胞死亡和/或抑制癌症或前癌细胞增殖的应用。本发明的萘醌衍生物与被称为β-拉帕醇（3,4-二氢-2,2-二甲基-2H-萘(1,2-b)吡喃-5,6-二酮）的化合物有关。
• Diquinones II the formation of dibenzofuran derivatives by rearrangement of diquinones
  作者：A.J. Shand、R.H. Thomson

  DOI：10.1016/0040-4020(63)85007-3

  日期：1963.1

  Several diquinones (I, III, V) undergo photochemical and/or thermal rearrangement to dibenzofuranquinones (II, IV, VI). Structure IV has been established by synthesis and unambiguous structures have been assigned to several of its isomers.

  几个二醌（I，III，V）经历光化学和/或热重排，生成二苯并呋喃醌（II，IV，VI）。通过合成已经建立了结构IV，并且已经将明确的结构分配给了它的几种异构体。
• [EN] FARNESOID X RECEPTOR AGONISTS<br/>[FR] AGONISTES DU RÉCEPTEUR DE FARNÉSOÏDE X
  申请人：SMITHKLINE BEECHAM CORP

  公开号：WO2009005998A1

  公开（公告）日：2009-01-08

  The present invention relates to famesoid X receptors (FXR, NR1H4) FXR is a member of the nuclear receptor class of ligand-activate transcription factors More particularly, the present invention relates to compounds useful as agonists for FXR, pharmaceutical formulations comprising such compounds, and therapeutic use of the same Novel isoxazole compounds are disclosed as part of pharmaceutical compositions for the treatment of a condition mediated by decreased FXR activity, such as obesity, diabetes, cholestatic liver disease, liver fibrosis, and metabolic syndrome

  本发明涉及法内索德X受体（FXR，NR1H4）。FXR是配体激活的转录因子核受体类的一个成员。更具体地说，本发明涉及作为FXR激动剂的化合物，包含该化合物的药物制剂，以及同一治疗用途。新颖的异恶唑化合物被披露作为药物组合物的一部分，用于治疗由FXR活性降低介导的状况，如肥胖、糖尿病、胆汁淤积性肝病、肝纤维化和代谢综合征。
• Transfer of Chirality in the Rhodium-Catalyzed Chemoselective and Regioselective Allylic Alkylation of Hydroxyarenes with Vinyl Aziridines
  作者：Tao-Yan Lin、Hai-Hong Wu、Jian-Jun Feng、Junliang Zhang

  DOI：10.1021/acs.orglett.7b01136

  日期：2017.6.2

  By taking advantage of chirality-transfer strategy, a chemo- and regioselective allylic alkylation of naphthols and phenols with vinylaziridines provides an atom-economic and efficient method for the synthesis of enantioenriched 2-vinyl-2-arylethylamine derivatives. Use of readily available starting materials, a broad substrate scope, high selectivity, mild reaction conditions, as well as versatile

  通过利用手性转移策略，萘酚和苯酚与乙烯基氮丙啶的化学和区域选择性烯丙基烷基化为合成对映体富集的2-乙烯基-2-芳基乙胺衍生物提供了一种原子经济有效的方法。使用容易获得的起始原料，广泛的底物范围，高选择性，温和的反应条件以及芳族乙胺产品的多功能官能化，使得该方法非常实用且有吸引力。